{"id":"NCT00428584","sponsor":"EMD Serono","briefTitle":"RNF and BetaseronÂ® Tolerability Study","officialTitle":"A Randomized, Multicenter, Two Arm, Open Label, Twelve Week Phase IIIb Study to Evaluate the Tolerability of Rebif (New Formulation) (IFN Beta-1a) and Betaseron (IFN Beta-1b) in IFN-naive Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Followed by a Single Arm, Eighty-two Week Minimum, Rebif (New Formulation) Only Safety Extension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-12","primaryCompletion":"2007-11","completion":"2009-09","firstPosted":"2007-01-30","resultsPosted":"2010-03-04","lastUpdate":"2013-08-07"},"enrollment":129,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Relapsing Remitting Multiple Sclerosis (RRMS)"],"interventions":[{"type":"DRUG","name":"New Formulation of rebif - human interferon beta-1a","otherNames":[]},{"type":"DRUG","name":"Interferon beta -1b","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"To evaluate the tolerability of a new formulation of rebif and Betaseron in subjects with relapsing-remitting multiple sclerosis (RRMS) by comparing the mean change in injection site pain scores from pre-injection to 30 minutes post therapy administration.","primaryOutcome":{"measure":"Visual Analog Scale (VAS) of Patient Reported Pain: Change in Mean VAS for the 21 Full-dose Injections at Pre-injection and 30 Minutes Post-injection Timepoints","timeFrame":"From pre-injection to 30 minutes post injection of the VAS pain scores across the first 21 injections of full dose therapy of a new formulation of rebif and Betaseron","effectByArm":[{"arm":"New Formulation of Rebif","deltaMin":0.43,"sd":2.06},{"arm":"Betaseron","deltaMin":0.4,"sd":1.64}],"pValues":[{"comp":"OG000 vs OG001","p":"0.524"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["23216674"],"seeAlso":["http://www.mslifelines.com"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":65},"commonTop":["General Disorders and Administration site condition","Infections and Infestations","Nervous system disorders","Musculoskeletal and connective tissue disorders","Investigations"]}}